- Home
- PLX vs BGX Comparison
PLX vs BGX Comparison
Compare PLX & BGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- BGX
- Stock Information
- Founded
- PLX 1993
- BGX 2010
- Country
- PLX United States
- BGX United States
- Employees
- PLX N/A
- BGX N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- BGX Trusts Except Educational Religious and Charitable
- Sector
- PLX Health Care
- BGX Finance
- Exchange
- PLX Nasdaq
- BGX Nasdaq
- Market Cap
- PLX 160.2M
- BGX 150.8M
- IPO Year
- PLX 1998
- BGX N/A
- Fundamental
- Price
- PLX $1.55
- BGX $12.13
- Analyst Decision
- PLX Strong Buy
- BGX
- Analyst Count
- PLX 1
- BGX 0
- Target Price
- PLX $15.00
- BGX N/A
- AVG Volume (30 Days)
- PLX 1.4M
- BGX 67.9K
- Earning Date
- PLX 05-09-2025
- BGX 01-01-0001
- Dividend Yield
- PLX N/A
- BGX 10.34%
- EPS Growth
- PLX N/A
- BGX N/A
- EPS
- PLX 0.05
- BGX N/A
- Revenue
- PLX $59,764,000.00
- BGX N/A
- Revenue This Year
- PLX $65.02
- BGX N/A
- Revenue Next Year
- PLX $57.34
- BGX N/A
- P/E Ratio
- PLX $32.18
- BGX N/A
- Revenue Growth
- PLX 0.18
- BGX N/A
- 52 Week Low
- PLX $0.82
- BGX $10.69
- 52 Week High
- PLX $3.10
- BGX $12.44
- Technical
- Relative Strength Index (RSI)
- PLX 30.03
- BGX 48.79
- Support Level
- PLX $1.54
- BGX $12.04
- Resistance Level
- PLX $1.79
- BGX $12.16
- Average True Range (ATR)
- PLX 0.11
- BGX 0.10
- MACD
- PLX -0.02
- BGX -0.02
- Stochastic Oscillator
- PLX 27.27
- BGX 24.24
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About BGX Blackstone Long Short Credit Income Fund
Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It seeks to achieve its investment objectives by employing a dynamic long-short strategy in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first- and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.